A Computationally Constructed lncRNA-Associated Competing Triplet Network in Clear Cell Renal Cell Carcinoma

Figure 6

The half maximal inhibitory concentration (IC₅₀) of gemcitabine (a), pazopanib (b), sunitinib (c), and XL-184 (d) in “HOTTIP high” group (≥median) and “HOTTIP low” group (<median) in ccRCC patients.

(a)

(b)

(c)

(d)